BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MRX-2843 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of MRX-2843\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04762199-2484@assetmemo.bio
DTSTAMP:20261121T005641Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:MRX-2843: Phase 1 readout est. (NCT04762199)
DESCRIPTION:MRX-2843\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: MRX-28
 43 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cel
 l Lung Cancer\nEstimated primary completion: 27 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/mrx-2843#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04762199
URL:https://assetmemo.bio/drug/mrx-2843#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
